Literature DB >> 8827858

Dermatoglyphic a-b ridge count as a possible marker for developmental disturbance in schizophrenia: replication in two samples.

L Fañanas1, J van Os, C Hoyos, J McGrath, C S Mellor, R Murray.   

Abstract

The aim of this study was to conduct an epidemiological analysis of quantitative dermatoglyphic traits as a marker of prenatal disturbance during the second trimester of life in schizophrenic patients. TFRC (Total Finger Ridge Count) and TABRC (Total a-b Ridge Count) were studied in a sample of 38 schizophrenic patients and 69 healthy individuals. A significant decrease of the a-b ridge count was found in patients compared to controls, with a significant linear trend across the population distribution (OR linear trend = 1.6; 95% CI = 1.0-2.4), indicating that the effect was not confined to a subgroup of cases with values in the lowest range. This finding was replicated in a second, larger sample (OR linear trend = 1.3; 95% CI = 1.0-1.8). The suggestion that a-b ridge count is associated with genetic risk for schizophrenia needs to be investigated further. TFRC did not distinguish between patients and controls. The a-b ridge count may be a continuous risk factor for later schizophrenia, pointing towards a disturbance occurring during the second trimester of prenatal life, a period of critical CNS growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827858     DOI: 10.1016/0920-9964(95)00013-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  The relationship of the number of Meissner's corpuscles to dermatoglyphic characters and finger size.

Authors:  Y K Dillon; J Haynes; M Henneberg
Journal:  J Anat       Date:  2001-11       Impact factor: 2.610

2.  The association between formal thought disorder and finger print asymmetry in children with a psychiatric disorder: an exploratory study.

Authors:  Esther I de Bruin; Pieter F A de Nijs; Frank C Verhulst; Anja C Huizink
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-07-18       Impact factor: 4.785

Review 3.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  The presentation of dermatoglyphic abnormalities in schizophrenia: a meta-analytic review.

Authors:  Shana Golembo-Smith; Deborah J Walder; Maureen P Daly; Vijay A Mittal; Emily Kline; Gloria Reeves; Jason Schiffman
Journal:  Schizophr Res       Date:  2012-10-29       Impact factor: 4.939

5.  Dermatoglyphic profile in 22q deletion syndrome.

Authors:  B Martín; L Fañanás; B Gutiérrez; E W C Chow; A S Bassett
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2004-07-01       Impact factor: 3.568

6.  A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors.

Authors:  E Bramon; R M Murray
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

7.  Dermatoglyphics in patients with schizophrenia.

Authors:  Fereshteh Shakibaei; Ghorban Ali Asadollahi; Amirpooyan Tabibi
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

8.  Mild dermatoglyphic deviations in adolescents with autism spectrum disorders and average intellectual abilities as compared to typically developing boys.

Authors:  Esther I de Bruin; John H Graham; Anneke Louwerse; Anja C Huizink
Journal:  Autism Res Treat       Date:  2014-11-19

9.  Directional and fluctuating asymmetry in finger and a-b ridge counts in psychosis: a case-control study.

Authors:  Sukanta Saha; Danuta Loesch; David Chant; Joy Welham; Ossama El-Saadi; Lourdes Fañanás; Bryan Mowry; John McGrath
Journal:  BMC Psychiatry       Date:  2003-03-23       Impact factor: 3.630

10.  Comparative Dermatoglyphic Study between Autistic Patients and Normal People in Iran.

Authors:  Mansoureh Kazemi; Mohammad Reza Fayyazi-Bordbar; Nasser Mahdavi-Shahri
Journal:  Iran J Med Sci       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.